Buy cheap Alendronate online
Home / Anti-osteoporosis / Alendronate
Alendronate
Alendronate is a bisphonosphonate drug. It is used to treat and prevent osteoporosis.
Synonyms: Fosamax
Alendronate 5 mg
Alendronate 10 mg
Alendronate 35 mg
Alendronate 70 mg
Indications:
Treatment and prevention of osteoporosis in postmenopausal women
For the treatment of osteoporosis, FOSAMAX (alendronate sodium) increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture.
For the prevention of osteoporosis, FOSAMAX (alendronate sodium) may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture.
How to take:
FOSAMAX (alendronate sodium) must be taken at least one-half hour before the first food, beverage, or medication of the day with plain water only. Other beverages (including mineral water), food, and some medications are likely to reduce the absorption of FOSAMAX. Waiting less than 30 minutes, or taking FOSAMAX (alendronate sodium) with food, beverages (other than plain water) or other medications will lessen the effect of FOSAMAX (alendronate sodium) by decreasing its absorption into the body.
FOSAMAX (alendronate sodium) should only be taken upon arising for the day. To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, a FOSAMAX (alendronate sodium) tablet should be swallowed with a full glass of water (6-8 oz). To facilitate gastric emptying FOSAMAX (alendronate sodium) oral solution should be followed by at least 2 oz (a quarter of a cup) of water. Patients should not lie down for at least 30 minutes and until after their first food of the day. FOSAMAX (alendronate sodium) should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences.
Precautions:
Causes of osteoporosis other than estrogen deficiency, aging, and glucocorticoid use should be considered.
Hypocalcemia must be corrected before initiating therapy with FOSAMAX. Other disorders affecting mineral metabolism (such as vitamin D deficiency) should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with FOSAMAX (alendronate sodium) .
Presumably due to the effects of FOSAMAX (alendronate sodium) on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur, especially in patients with Paget's disease, in whom the pretreatment rate of bone turnover may be greatly elevated and in patients receiving glucocorticoids, in whom calcium absorption may be decreased.
Ensuring adequate calcium and vitamin D intake is especially important in patients with Paget's disease of bone and in patients receiving glucocorticoids.
Treatment and prevention of osteoporosis in postmenopausal women
For the treatment of osteoporosis, FOSAMAX (alendronate sodium) increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture.
For the prevention of osteoporosis, FOSAMAX (alendronate sodium) may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture.
How to take:
FOSAMAX (alendronate sodium) must be taken at least one-half hour before the first food, beverage, or medication of the day with plain water only. Other beverages (including mineral water), food, and some medications are likely to reduce the absorption of FOSAMAX. Waiting less than 30 minutes, or taking FOSAMAX (alendronate sodium) with food, beverages (other than plain water) or other medications will lessen the effect of FOSAMAX (alendronate sodium) by decreasing its absorption into the body.
FOSAMAX (alendronate sodium) should only be taken upon arising for the day. To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, a FOSAMAX (alendronate sodium) tablet should be swallowed with a full glass of water (6-8 oz). To facilitate gastric emptying FOSAMAX (alendronate sodium) oral solution should be followed by at least 2 oz (a quarter of a cup) of water. Patients should not lie down for at least 30 minutes and until after their first food of the day. FOSAMAX (alendronate sodium) should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences.
Precautions:
Causes of osteoporosis other than estrogen deficiency, aging, and glucocorticoid use should be considered.
Hypocalcemia must be corrected before initiating therapy with FOSAMAX. Other disorders affecting mineral metabolism (such as vitamin D deficiency) should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with FOSAMAX (alendronate sodium) .
Presumably due to the effects of FOSAMAX (alendronate sodium) on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur, especially in patients with Paget's disease, in whom the pretreatment rate of bone turnover may be greatly elevated and in patients receiving glucocorticoids, in whom calcium absorption may be decreased.
Ensuring adequate calcium and vitamin D intake is especially important in patients with Paget's disease of bone and in patients receiving glucocorticoids.